HomeIngredientsShiitake (Lentinula edodes)
In brief

The scientist who recovered a long-known truth

For centuries Eastern wisdom linked mushrooms with health and life — Western medicine dismissed it as a fairy tale. Dr Kisaku Mori decided in 1936 to check what was really hiding behind those “stories.”

Thousands of studies. Collaboration with scientists from all over the world. The book “Mushrooms as Health Foods.” Diabetes, flu, liver diseases, cancer — in every field Lentinula edodes showed something that made it worth continuing. His work became the clinical basis for hundreds of independent studies carried out around the world even after his death.

Western medicine did not start treating with mushrooms. It only finally began to document it.

Why does one mushroom affect so many different functions?

Such a question can sound suspicious. If something affects everything — it usually means it affects nothing.

In the case of Lentinula edodes the answer lies in the structure: this mushroom contains several different, chemically unrelated active substances, each acting by its own biochemical mechanism.

This is not one “miracle” compound. It is a mushroom with several different, independently acting components.

Effect on immunity and significance in oncology

The immunomodulating effect of Lentinula edodes is its most scientifically documented aspect. Hundreds of clinical studies confirm:

Effect on the tumor: suppresses the multiplication and growth of cancer cells; promotes apoptosis of cancer cells — natural cell death; blocks angiogenesis — the growth of the blood vessels a tumor needs.

Effect on immunity: increases the activity of NK cells (natural killers); activates macrophages and T cells; promotes the production of cytokines (IL-2, IL-12, IFN-γ); reduces the amount of IAP (immunosuppressive acidic protein); activates T cells (chemotherapy reduces their number — restoring it is essential).

Used together with chemotherapy: strengthens the effect of chemotherapy; reduces side effects; improves quality of life; extends survival.

In Japan, mushroom-polysaccharide preparations have been a standard adjunct treatment in oncology since 1985. Not alternative medicine. Standard practice.

Do not wait for the system to change. Take control of your health now. Lentinan AXT from Zenius Labs™ is a mushroom-polysaccharide formula that does not need your belief. Only your decision.

Eritadenine and cholesterol metabolism

This is an aspect rarely discussed, but it is clinically documented.

Eritadenine — a compound found almost exclusively in Lentinula edodes mushrooms — acts through COMT (catechol-O-methyltransferase) inhibition. Its mechanism differs from statins: instead of blocking cholesterol production in the liver, eritadenine promotes its excretion with bile and improves the LDL-to-HDL ratio.

If a statin and eritadenine are two different paths to the same goal, then a cholesterol-caused heart attack and a person who regularly takes Lentinula edodes extract are two different scenarios. Human studies show a statistically significant reduction of total and LDL cholesterol over 4–8 weeks.

This does not mean extracts can replace statins at a critical level. But for prevention and together with dietary correction — this is not “helps a little,” but a scientifically grounded choice.

Antiviral and antibacterial properties

Lentinacin (KS-2) activates interferon production — the body’s main antiviral defense system. This effect has been studied with influenza, HSV (herpes simplex) and HIV viruses.

Lentinan has demonstrated activity against bacteria and fungal infections in in-vitro studies. It is not a substitute for antibiotics, but an activated immune system naturally strengthens resistance to seasonal illnesses — and study data confirm this.

Among the diseases Dr Mori studied: flu, stomach ulcer, AIDS, arthritis, skin diseases. Some of these indications now already have clinical evidence; others are studied further.

A mushroom or an extract — these are not the same

Lentinula edodes can be eaten as food. Tasty. Nutritious. But the amount of active substances obtained from food, and the amount in a concentrated extract — that is not “slightly different.” It is the comparison of a bicycle and an aeroplane.

Water-based extraction is the only way to obtain the mushroom polysaccharides in a biologically available form. Alcohol-based extraction is cheaper in production, but the polysaccharides are broken down in this process or do not pass into the final product.

A standardised polysaccharide percentage on the packaging is not a marketing term. It shows how much active substance is actually in the capsule. 30% and 5% extracts differ by 6 times in the amount of active substances. The smallest clinically significant dose is 1,200 mg of 30% extract per day.

If the packaging does not state the polysaccharide concentration — it is most likely dried, ground mushrooms. Not an extract. What you will get is just a large portion of mushroom powder.

Frequently Asked Questions

What is Lentinula edodes and how does it differ from ordinary mushrooms?

Lentinula edodes is the scientific name for shiitake. It differs from ordinary edible mushrooms in having several unique active compounds — lentinan, eritadenine, lentinacin — each working through a different biochemical mechanism. Eastern medicine used it therapeutically for thousands of years before Western science began documenting it.

Can a Lentinula edodes extract be used alongside chemotherapy?

In Japan this has been standard practice since 1985. Hundreds of clinical studies are examined for lentinan preparations strengthening chemotherapy, reducing side effects and improving quality of life. Consult your treating doctor first, especially if you take immunosuppressants.

How does shiitake affect cholesterol?

Eritadenine, found almost exclusively in Lentinula edodes, acts on cholesterol metabolism in the liver via COMT inhibition — a different mechanism from statins. It is studied as a prevention support alongside dietary change, but does not replace statins at critical levels.

Is eating shiitake the same as taking an extract?

No. The active polysaccharides dissolve only in water, so only a concentrated, water-based extract delivers the compounds that matter. Alcohol extracts and simple mushroom powders are far too weak for a therapeutic effect.

References
  1. Brown GD, et al. Dectin-1 mediates the biological effects of beta-glucans. J Exp Med. 2003. PubMed
  2. Chanput W, et al. β-Glucans are involved in immune-modulation of THP-1 macrophages. Mol Nutr Food Res. 2012. PubMed
  3. Ren G, et al. Lentinan modulates the intestinal microbiota and enhances antitumor efficacy. Int J Biol Macromol. 2019. PubMed
  4. Wasser SP, et al. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol. 2002. PubMed
  5. Israilides C, et al. In vitro cytostatic and immunomodulatory properties of Lentinus edodes. Phytomedicine. 2008. PubMed
  1. Okamoto T, et al. Lentinan suppresses expression of cytochrome P450 enzymes. Biofactors. 2004. PubMed
  2. Bisen PS, et al. Lentinus edodes: A Macrofungus with Pharmacological Activities. Curr Med Chem. 2010. BegellHouse
  3. Ina K, et al. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem. 2013. PubMed Central
  4. Zhang Y, et al. Lentinus edodes modulates macrophage activity. Food Chem. 2002. PubMed
  5. Gordon M, et al. A phase I study of cimetidine and lentinan in patients with advanced malignancies. J Clin Oncol. 2004. PubMed
  6. Clynes RA, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000. PubMed
  7. Modak S, et al. Rituximab therapy of lymphoma is enhanced by orally administered beta-glucans. Leuk Res. 2005. PubMed
  8. Ogawa K, et al. Enhanced therapeutic effect against liver metastasis of colon cancer with combined use of lentinan and tegafur/uracil. Oncol Rep. 1997. PubMed
  9. Chihara G, et al. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes. Nature. 1970. Nature
  10. Maeda YY, et al. Antitumor activity of polysaccharides. Cancer Res. 1970. Cancer Research
  11. Chihara G, et al. Fractionation and purification of the polysaccharides with marked antitumor activity from Lentinus edodes. Cancer Res. 1970. Nature
  12. Chihara G, et al. Inhibition of mouse sarcoma 180 by lentinan. Int J Cancer. 1969. Wiley
  13. Hamuro J, et al. Macrophage activation by lymphokines in lentinan-treated mice. Int J Immunopharmacol. 1980. PubMed
  14. Yoshino S, et al. Enhancement of lymphokine-activated killer cell activity by lentinan. Oncology. 2007. PubMed
  15. Aoki T, et al. Lentinan activates macrophages and NK cells. Jpn J Cancer Res. 2000. PubMed
  16. Kosaka A, et al. Macrophage activation by combined treatment with cyclophosphamide and lentinan. Jpn J Exp Med. 2009. PubMed
  17. Takeshita K, et al. Activation of peritoneal macrophages by lentinan. Chem Pharm Bull. 1996. PubMed
  18. Takeshita K, et al. T-cell activation by lentinan combined with other immunomodulators. Immunopharmacology. 2004. PubMed
  19. Maeda M, et al. Augmentation of T-lymphocyte function by lentinan. Jpn J Cancer Res. 1978. PubMed
  20. Hamuro J, et al. NK activity augmentation by lentinan with special reference to immune adherence. Int J Immunopharmacol. 1976. PubMed
  21. Maeda YY, et al. Antitumor activity and murine NK cell activation by polysaccharides. J Natl Cancer Inst. 1974. PubMed
  22. Hamuro J, et al. Enhancement of NK activity by lentinan in aged mice. J Immunopharmacol. 1985. PubMed
  23. Aoki T, et al. Restoration of immune response to lentinan in advanced cancer patients. Cancer Immunol Immunother. 1984. PubMed
  24. Herr HW, et al. Intravesical interleukin-2 immunotherapy in superficial bladder cancer. J Urol. 1986. PubMed
  25. Cheung NK, et al. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002. PubMed
  26. Uno K, et al. Suppression of TH2 responses by lentinan through modulation of IL-4 and IL-5. Int Immunopharmacol. 2000. PubMed
  27. Wakui A, et al. Lentinan inhibits allergic asthmatic response. Int Arch Allergy Immunol. 2001. PubMed
  28. Matsuoka H, et al. Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 1997. PubMed
  29. Zhang M, et al. Dietary supplementation of mushroom polysaccharides and survival outcomes. Int Immunopharmacol. 2011. PubMed
  30. Nakano H, et al. A multi-institutional prospective study on lentinan and survival in gastric cancer. Jpn J Clin Oncol. 1999. PubMed
  31. Zhang M, et al. Survival outcomes with lentinan supplementation – multicenter review. Int Immunopharmacol. 2011. PubMed
  32. Taguchi T, et al. Clinical effects of schizophyllan (SPG) on gastric cancer – a randomized study. Biotherapy. 1995. PubMed
  33. Fujimoto S, et al. Antitumor effect of lentinan combined with mitomycin C. Cancer Treat Rep. 1991. PubMed
  34. Nakano H, et al. Lentinan and survival in gastric cancer. Jpn J Clin Oncol. 1999. PubMed
  35. Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother. 2007. PubMed
  36. Iino Y, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of gastric cancer. Anticancer Res. 1995. PubMed
  37. Liu J, et al. Lentinan and antitumor immunotherapy: meta-analysis. PLOS ONE. 2017. PubMed Central
  38. Sakagami H, et al. Prooxidant action of two antioxidants: ascorbic acid and gallic acid. Anticancer Res. 2011. PubMed
  39. Xu X, et al. Lentinula edodes polysaccharides and their immunostimulatory effects. Int J Biol Macromol. 2014. PubMed
  40. Oba K, et al. Individual patient based meta-analysis of lentinan in unresectable gastric cancer. Cancer Immunol Immunother. 2009. PubMed
  41. Sugano N, et al. Anticarcinogenic actions of water-soluble and alcohol-insoluble fractions from shiitake. Cancer Lett. 1982. PubMed
  42. Zheng R, et al. Lentinan inhibits colorectal carcinoma cell growth. Exp Ther Med. 2013. PubMed
  43. Yao JY, et al. Lentinan potentiates anti-tumor effect via inhibition of angiogenesis. Food Chem Toxicol. 2018. PubMed Central
  44. Kimura Y, et al. TS-1 and lentinan combination immunochemotherapy for gastric cancer. Gan To Kagaku Ryoho. 2003. PubMed
  45. Matsuoka H, et al. Lentinan potentiates immunity – confirmatory study. Anticancer Res. 1997. PubMed
  46. Ishigami H, et al. Relationship between prolonged survival and changes of serum IAP after lentinan treatment. Nihon Geka. 1992. PubMed
  47. Gil-Ramírez A, et al. Water-soluble compounds from Lentinula edodes influencing HMG-CoA reductase and cholesterol metabolism. J Agric Food Chem. 2016. PubMed
  48. Yang H, et al. Lentinus edodes promotes fat removal in hypercholesterolemic mice. Exp Ther Med. 2013. PubMed
  49. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
  50. Oba K et al. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer research. 2009. PubMed
  51. Wang Y et al. Investigation on the efficiency of lentinan for injection combining cisplatin on treating malignant pleural effusion based on systematic review and meta-analysis. Medicine. 2024. PubMed
  52. Zhang M et al. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. Progress in molecular biology and translational science. 2019. PubMed
  53. Yin X et al. A meta-analysis of lentinan injection combined with chemotherapy in the treatment of nonsmall cell lung cancer. Indian journal of cancer. 2015. PubMed
  54. Baral B Holistic Evaluation of Shiitake mushrooms (Lentinula edodes): Unraveling Its Medicinal and Therapeutic Potentials. Chemistry & biodiversity. 2025. PubMed
  55. Ooi SL et al. Modified Rice Bran Arabinoxylan by Lentinus edodes Mycelial Enzyme as an Immunoceutical for Health and Aging-A Comprehensive Literature Review. Molecules (Basel, Switzerland). 2023. PubMed
  56. Choi JY et al. Dietary supplementation with rice bran fermented with Lentinus edodes increases interferon-γ activity without causing adverse effects: a randomized, double-blind, placebo-controlled, parallel-group study. Nutrition journal. 2014. PubMed
  57. Gaullier JM et al. Supplementation with a soluble β-glucan exported from Shiitake medicinal mushroom, Lentinus edodes (Berk.) singer mycelium: a crossover, placebo-controlled study in healthy elderly. International journal of medicinal mushrooms. 2011. PubMed
  58. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
  59. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
  60. Tanaka H et al. Impact of adjuvant immunochemotherapy using protein-bound polysaccharide-K on overall survival of patients with gastric cancer. Anticancer research. 2012. PubMed
  61. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
  62. Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
  63. Standish LJ et al. Trametes versicolor mushroom immune therapy in breast cancer. Journal of the Society for Integrative Oncology. 2008. PubMed
  64. Eliza WL et al. Efficacy of Yun Zhi (Coriolus versicolor) on survival in cancer patients: systematic review and meta-analysis. Recent patents on inflammation & allergy drug discovery. 2012. PubMed
  65. He Z et al. Polysaccharide-Peptide from Trametes versicolor: The Potential Medicine for Colorectal Cancer Treatment. Biomedicines. 2022. PubMed
  66. Chang Y et al. Preclinical and clinical studies of Coriolus versicolor polysaccharopeptide as an immunotherapeutic in China. Discovery medicine. 2017. PubMed
  67. Ziaja-Sołtys M et al. Exploring the Anticancer Potential of Coriolus versicolor in Breast Cancer: A Review. Current issues in molecular biology. 2025. PubMed
  68. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
  69. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
  70. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
  71. Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
  72. He J et al. Astaxanthin Alleviates Oxidative Stress in Mouse Preantral Follicles and Enhances Follicular Development Through the AMPK Signaling Pathway. International journal of molecular sciences. 2025. PubMed
  73. Akramiene D et al. Effects of beta-glucans on the immune system. Medicina (Kaunas, Lithuania). 2007. PubMed
  74. Ross GD et al. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology. 1999. PubMed
  75. Li B et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. Journal of immunology (Baltimore, Md. : 1950). 2006. PubMed
  76. Liu J et al. Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Experimental and molecular pathology. 2009. PubMed
  77. Xia Y et al. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. Journal of immunology (Baltimore, Md. : 1950). 1999. PubMed
  78. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
  79. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
  80. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
  81. Jia XM et al. CARD9 mediates Dectin-1-induced ERK activation by linking Ras-GRF1 to H-Ras for antifungal immunity. The Journal of experimental medicine. 2014. PubMed
  82. Bode K et al. Dectin-1 Binding to Annexins on Apoptotic Cells Induces Peripheral Immune Tolerance via NADPH Oxidase-2. Cell reports. 2019. PubMed
  83. Zou X et al. Radioprotective effect of edible and medicinal mushrooms against ionizing radiation: Components, potential mechanisms, and applications. Food research international (Ottawa, Ont.). 2025. PubMed
  84. Dan A et al. Therapeutic Effects of Medicinal Mushrooms on Gastric, Breast, and Colorectal Cancer: A Scoping Review. Cureus. 2023. PubMed
  85. Abidin MHZ et al. Antiatherogenic Potential of Extracts from the Gray Oyster Medicinal Mushroom, Pleurotus pulmonarius (Agaricomycetes), In Vitro. International journal of medicinal mushrooms. 2018. PubMed
  86. Zhang X et al. Edible mushroom polysaccharides: Structural characteristics, chemical modification strategies, and structure-activity relationship: A review. International journal of biological macromolecules. 2025. PubMed
  87. Narayanan S et al. Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies. Current oncology reports. 2023. PubMed
  88. Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
  89. Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
  90. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
  91. Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed